Milestone Pharmaceuticals Inc (OQ:MIST)

Business Focus: Bio Therapeutic Drugs

Sector:  Healthcare Industry:  Biotechnology & Medical Research
 
See Regulatory Filings on SEC
Company Contact
Address: 420-1111 boul. Dr.-Frederik-Philips
MONTREAL QC H4M 2X6
Tel: 1-212-6001902
Website: https://www.milestonepharma.com
IR: See website
<
Key People
Joseph Oliveto
President, Chief Executive Officer, Director
Amit Hasija
Chief Financial Officer, Executive Vice President of Corporate Development
Jeffrey Nelson
Chief Operating Officer
David Bharucha
Chief Medical Officer
Lorenz Muller
Chief Commercial Officer
 
Business Overview
Milestone Pharmaceuticals Inc. is a Canada-based biopharmaceutical company. The Company is focused on the development and commercialization of cardiovascular medicines. Its lead product candidate, etripamil, is a potent rapid-onset calcium channel blocker that the Company designed and is developing as a rapid-onset nasal spray to be administered by patients. The Company is also focused on developing etripamil to treat paroxysmal supraventricular tachycardia (PSVT) with a subsequent indication to treat atrial fibrillation with rapid ventricular rate (AFib-RVR) and other cardiovascular indications.
Financial Overview
For the fiscal year ended 31 December 2023, Milestone Pharmaceuticals Inc revenues decreased 80% to $1M. Net loss increased 2% to $59.7M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Commercial activities increase of 77% to $13.7M (expense), Stock-based Compensation in SGA increase of 15% to $4.8M (expense).
Employees: 47 as of Dec 31, 2023
Reporting Currency: U.S. Dollars
Enterprise value: $74.12M as of Mar 31, 2024
Annual revenue (TTM): $1.00M as of Mar 31, 2024
EBITDA (TTM): -$61.01M as of Mar 31, 2024
Net annual income (TTM): -$59.69M as of Mar 31, 2024
Free cash flow (TTM): -$46.54M as of Mar 31, 2024
Net Debt Last Fiscal Year: N/A
Shares outstanding: 53,149,778 as of Mar 21, 2024
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.